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Improvements in instrumentation, such as NIR intraoperative reflectance imaging, high-spatial resolution endomicroscopy and fluorescence tomography, have led to further improvement of NIR imaging 15 , 31 . NIR imaging agents such as indocyanine green have already been used for human breast cancer imaging and other clinical applications 16, 17 . Meincke et al. 18 have shown sensitive and selective binding of NIR fluorescent dye for CXCR4 to cancer cells in mouse xenograft models of human breast cancer and glioma.
In the current study, we synthesized a peptide that target to CXCR4 and labeled with IR-783 dye and developed a novel CXCR4-targeted NIR fluorescent imaging agent (CXCR4-IR-783). Then, we examined the selectivity and sensitivity of this agent using both cultured osteosarcoma cells and a mouse xenograft model of human osteosarcoma.
Results
Osteosarcoma cells overexpressing CXCR4 exhibit a preferential time-and dose-dependent uptake of CXCR-IR-783. Real-time qRT-PCR and Western blotting assays showed significantly higher CXCR4 expression at both the mRNA and protein levels in F5M2 cells (with high propensity for pulmonary metastasis) than in F4 cells (with low propensity for pulmonary metastasis) (Supplementary Fig.  S1A and S1B). Confocal immunofluorescent (IF) microscopy confirmed higher CXCR4 expression in F5M2 cells than in F4 cells (Figs 1A,B, upper panels). A polypeptide composed of 10 amino acids targeting CXCR4 was synthesized ( Supplementary Fig. S2A ) and then labeled with IR-783 dye to generate CXCR4-targeted NIR fluorescent imaging agent CXCR4-IR-783 ( Supplementary Fig. S2B ). Specificity of the NIR fluorescent imaging agent was confirmed by downregulation of CXCR4 expression with a shRNA against CXCR4 (Supplementary Fig. S1A and S1B; Fig. 1C , upper panel). Upon exposure to CXCR4-IR-783 (5 nM), the NIR fluorescent signal was significantly higher in F5M2 than in F4 cells (P < 0.05, Fig. 1D ).
The NIR fluorescence intensity in F5M2 cells was increased by CXCR4-IR-783 (10 −3 to 1 nM), but not by free IR-783, in a concentration-dependent manner ( Fig. 1E ): the signal was detectable at 10 −2 nM and reached 102.2 ± 4.55 at 6 hr after exposure to 1 nM CXCR4-IR-783 (Fig. 1F) . The signal also depended on the cell density within a range from 1 × 10 2 to 5 × 10 5 F5M2 cells (Fig. 1G ).
Mouse human osteosarcoma xenografts show preferential uptake and retention of CXCR4-IR-783. Intense NIR fluorescence signal at the site of inoculation was detectable in mice on 5-25 days post inoculation with F5M2 cells ( Fig. 2A) , and the tumor-to-background ratio (TBR) remained stable throughout the 25-day experiments (Fig. 2B) .The NIR fluorescence signal intensity was significantly higher in mice inoculated with F5M2 than with F4 cells (Fig. 2C , first and last row). The TBR was 4.87 vs. 2.24 for F5M2 and F4 xenografts, respectively (Fig. 2D ). Pathological examination confirmed the presence of tumor in the bone (Fig. 2E) . Immunohistochemistry (IHC) of tumor xenograft revealed higher CXCR4 expression in F5M2 xenografts than F4 xenografts (Fig. 2E) . We also demonstrated distribution of the peptide agent in the whole body, including the liver and submandibular gland.
CXCR4-IR-783 allows detection of lung metastasis.
Our previous study 19 showed that the metastatic nodules in the lungs became detectable six weeks after inoculation of F5M2 cells. In the current study, micro-CT scan revealed nodules in the lungs at 6 weeks after inoculation with F5M2 cells (Fig. 3A) . NIR imaging revealed fluorescent signal in the lungs of mice bearing F5M2 xenografts, at sites suggested by CT imaging (Fig. 3B) . Ex vivo imaging confirmed the NIR signals in the submandibular gland, lung metastatic tumor, liver, kidney and primary tumor (Fig. 3C) . The presence of osteosarcoma cells in the lung tissues was confirmed by histopathologic evaluation with H&E staining (Fig. 3D) . CXCR4 expression in the metastatic osteosarcoma tissue was demonstrated by IHC (Fig. 3E) . When molecular imaging showed negative results ( Supplementary Fig. S3A and S3B), histopathologic examination also confirmed the absence of lung nodules ( Supplementary Fig. S3C ). In IHC analysis, CXCR4 expression was not detectable in healthy lungs ( Supplementary Fig. S3D ). NIR fluorescence signal appeared in the lungs of mice bearing F5M2 xenografts as early as four weeks post tumor implantation ( Fig. 3F ) with < 1 mm (as small as 200 μ m) lung metastatic nodules (Fig. 3G) . Micro-metastasis in the lungs was confirmed by histopathologic evaluation with H&E staining (Fig. 3H ) and by IHC for CXCR4 (Fig. 3I) . Micro-CT scan also detected micro-metastasis in the lungs (Fig. 3J ) but 18 F-FDT PET scan of the chest failed to reveal any change in glucose uptake (Fig. 3K ).
CXCR4-IR-783 exhibits time-dependent clearance from normal mouse organs. The tumor and muscle ratio of CXCR4-IR-783 increased from day 1 and peaked at day 3 post injection of CXCR4-IR-783 in mice bearing F5M2 xenograft (Fig. 4A,B) . The liver-to-tumor ratio of CXCR4-IR-783 reached a peak value (5.5 ± 0.7) at 4 hours and declined to 1.1 ± 0.2 at day 7 post injection ( Fig. 4B) . Contiguous NIR imaging showed a steady decline in NIR fluorescence intensity in the lungs, heart and brain (Fig. 4C,D) and the liver, spleen and other organs (Fig. 4E) . Histological examination failed to reveal the presence of metastatic osteosarcoma in these organs, including the submandibular gland and liver, (Fig. 4F) . 
Discussion
Lack of effective imaging modalities for detection of clinically non-detectable micro-metastases of osteosarcoma hampers its management. NIR fluorescence cancer imaging has demonstrated excellent sensitivity and high spatial resolution with real-time display 13, 14 . In the current study, we developed a novel CXCR4 targeted NIR fluorescent imaging agent (CXCR4-IR-783). This agent exhibited superior selectivity in detection of CXCR4 expression in osteosarcoma cells both in vitro and in vivo. More importantly, NIR fluorescence imaging using CXCR4-IR-783 detected the pulmonary metastases of osteosarcoma that were not detected by 18 F-FDG PET. NIR fluorescence cancer imaging using a human recombinant SDF-1 conjugated with IRDye800CW has been attempted for breast cancer in a mouse xenograft model 18 , but there has been no prior study on the use of CXCR4-IR-783 for imaging osteosarcoma and its metastases. Our study provides direct evidence that NIR fluorescence imaging using CXCR4-IR-783 visualizes osteosarcoma and its metastases.
NIR imaging uses near-infrared light (wavelength: 650-900 nm), and thus has deeper tissue penetration due to less absorption by hemoglobin and water, and low background due to less autofluorescence from surrounding tissues 13, 20, 21 . Moreover, NIR dyes such as indocyanine green have low and negligible toxicity and are widely used in clinical applications, including cancer detection/characterization, lymphatic imaging and surgical/endoscopic guidance 13, 14, 20, 22 . CXCR4 is implicated in tumor progression, including angiogenesis and metastasis 23, 24 . Increasing evidence indicates that CXCR4 is expressed in various stages of tumor and its expression in the primary lesions correlates with metastasis and poor survival of patients with breast cancer, cervical adenocarcinoma and other cancer types 12, 24, 25 . CXCR4 is also expressed in primary and metastatic lesions of human osteosarcoma and associated with metastasis and poor prognosis of osteosarcoma 7, 26 . Molecular imaging is highly dependent on a specific molecular target 14, 27 . A successful imaging agent should exhibit consistent binding affinity for its molecular target regardless of the mutation status at the protein level 28 . In the current study, the peptide agents, CXCR4-IR-783, were screened, minimized and modified to ensure the final product binding to the conservative region of CXCR4 receptor. Compared to free IR-783, CXCR4-IR-783 was associated with significantly higher NIR fluorescence intensity in F5M2 cells. Meanwhile, we demonstrated a higher uptake of CXCR4-IR-783 by osteosarcoma cells overexpressing CXCR4 (F5M2) than osteosarcoma cells expressing low level of CXCR4 (F4). Our peptide imaging yielded similar results both in vitro and in vivo. The two cell lines were derived from the same parental osteosarcoma cell line SOSP-9607 19 , suggesting that difference in CXCR4 expression is responsible for binding difference. Furthermore, a CXCR4 shRNA markedly attenuated CXCR4-IR-783 NIR fluorescence intensity in F5M2 cells, adding further support to the binding specificity of CXCR4-IR-783.
Upon presentation, approximately 80% of osteosarcoma patients have metastatic diseases, and many patients also have undetectable pulmonary micro-metastases 29 . Yet, only a very small portion of these patients are diagnosed with the current methods 29, 30 . In our experiments, the only clinically available molecular imaging modality, 18 F-FDG PET, failed to show increased glucose uptake in the metastatic lesions. 18 F-FDG PET imaging relies on glucose level to differentiate disease region but the limitation of spatial resolution of PET detector and low glucose metabolic status make it impossible in this study. Micro-CT provides approximate robust anatomical information and evidence for highly probable metastatic lesions in the lungs. However, it cannot detect the disease components at the molecular level. Determination of the disease components at the molecular levels could support CT findings since these lesions tend to appear as healthy tissue in X-ray. In the current study, NIR fluorescence imaging using CXCR4-IR-783 detected micro-metastasis as small as 200 μ m in diameter, indicating that CXCR4-targeted imaging could improve detection of CXCR4-positive osteosarcoma metastasis.
CXCR4 is widely expressed in monocytes and macrophages, and normal tissues such as the colon, kidney, and liver 23 . Our in vivo successive imaging showed that the tumor to muscle ratio peaked at 3 days after injection, and exceeded the liver-to-tumor ratio. Ex vivo distribution analysis revealed that, in addition to the tumor, the signal concentrated in the liver, kidney, spleen, stomach, intestine, and submandibular gland upon initial injection of CXCR4-IR-783, but the signal intensity decreased over time, suggesting that, within proper window, this probe could be used to detect osteosarcoma with relative high signal-to-noise ratio. Although histological examination failed to reveal the presence of metastatic osteosarcoma in the submandibular and liver, the presence of NIR signal in these organs is too high and requires further investigation. So CXCR4-IR-783 is not optimal. Further modification of the probe is currently carried out in our laboratory.
In conclusion, we developed a novel CXCR4-targeted NIR fluorescent imaging agent (CXCR4-IR-783). This probe could detect both primary and micro-metastatic lung lesions of CXCR4-overexpressing osteosarcoma. NIR fluorescence imaging with this agent, combining with other imaging modalities (such as X-ray) which can provide anatomical information, will enhance the detection of osteosarcoma.
Materials and Methods
Ethics statement. All the animal operations were approved by the Ethics Review Committee of the Fourth Military Medical University, Xi'an, Shaanxi, China. The methods were carried out in accordance with the approved guidelines.
Cells and lentiviral infections. F5M2, a human osteosarcoma cell line with high propensity for pulmonary metastasis, and F4, a human osteosarcoma cell line with low propensity for pulmonary metastasis, were previously described 19 and grown in RPMI 1640 (HyClone, Thermo Scientific, Waltham, Massachusetts) supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/mL), streptomycin (100 μ g/mL), and glutamine (2 mM).
For generation of stable CXCR4-knockdown cells, lentivirus vectors expressing short-hairpin RNA (shRNA; sequence, 5′ -TCCTGTCCTGCTATTGCATTA-3′ ) targeting CXCR4 (Hanbio Biotechnology, Shanghai, China) were transfected into 293 T cells using Lipofectamine 2000 (Invitrogen, Carlsbad, California) and lentiviral packaging mix according to the manufacturer's protocol. F5M2 cells were then transfected with the lentiviruses at a multiplicity of infection (MOI) of 100. Stable CXCR4-knockdown cells were selected with puromycin (3 mg/mL) (Hanbio Biotechnology) and confirmed real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting assays as detailed elsewhere in the text.
Immunofluorescence confocal microscopy. Cells were plated onto Millicell EZ SLIDE 8-well glass (Millipore, Darmstadt, Germany) for 12 h and then fixed with 4% paraformaldehyde followed by permeabilization with phosphate buffered saline (PBS) containing 0.1% Triton X-100 (PBST). After blocking with normal goat serum, the cells were incubated with anti-CXCR4 antibodies (R&D Systems) at 4 °C overnight. After three washes with 0.1% PBST, the cells were incubated with secondary FITC-conjugated sheep anti-mouse IgG (Sigma) and mounted with DAPI (Sigma) after wash with PBST. The cellular localization and expression of CXCR4 were examined under a confocal microscope (Olympus, Tokyo, Japan).
NIR fluorescence microscopy. The peptide agents were screened, minimized and modified to ensure the final product binding to the conservative region of CXCR4 receptor. Such approach will maintain the binding capability even after the cancer cells mutation during their progression. A detail design, modification, stability, structure change the binding affinity and pathway function for different structure will be summarized and published in a separate chemistry journal. Briefly, a peptide agent that target to CXCR4 was synthesized at Department of Radiology, Baylor College of Medicine, Houston, TX using Fmoc-based solid-phase peptide synthesizer and labeled with IR-783 dye. The conjugate was purified by reverse-phase high-performance liquid chromatography (HPLC) and was certificated by mass spectrometry, analytic HPLC, and fluorescent spectrophotometry. Exponentially growing F5M2 and F4 cells were seeded at a density of 2 × 10 4 cells/well in 4-well glass slides (Millipore) in RPMI-1640 containing 10% FBS. After an overnight growth, the cells were treated with IR-783 or CXCR4-IR-783 over a 1000-fold range from 10 −3 to 1 nM or the indicated periods of time as detailed elsewhere in the text. Then, the cells were washed thrice with PBS. After fixation with 4% formaldehyde, the cell nuclei of the cells were stained by DAPI. Images were captured using a Leica TCS confocal microscope (Leica TCS SP5, Germany) equipped with an excitation light source and emission filters to detect and separate signals from near infrared agent (IR-783-CXCR4 and IR-783) and DAPI. Images were scanned and captured at 60× and 360× magnifications and mean fluorescence intensity was calculated.
Animal xenograft studies. Four-week-old female BALB/c nude (nu/nu) mice (the Animal Center, the Fourth Military Medical University, Xian, Shaanxi, China) were housed under pathogen-free conditions at 26-28 °C with 50-65% humidity. Totally 5 × 10 5 F5M2 or F4 cells in 50 μ L PBS were injected into the right hind tibia as previously descripted 19 . Tumors were allowed to grow six weeks to allow metastasis. No mice died before six weeks.
Animal imaging studies. Mice bearing tumor xenografts were injected intravenously with IR-783-CXCR4 or IR-783 200 μ l a mouse. Imaging was performed 4 h to 9 days after the injection using Kodak In-Vivo Multispectral System FX (Carestream Health Molecular Imaging, New Haven, Connecticut) and the Carestream Molecular Imaging (MI) Software while the mice were immobilized by inhalational isoflurane (Jiu Pai Laboratories, China) and kept warm at 37 °C. Excitation and emission wavelengths were fixed at 760 and 830 nm, respectively. In addition, ex vivo imaging was performed after the removal of organs or tumors following sacrifice of the animals by cervical dislocation. The images and data were analyzed using the Carestream Molecular Imaging (MI) Software and the open-source software Image J (http://rsbweb.nih.gov/ij/) to distinguish autofluorescence from the normal tissues and fluorescence from the tumors. Fluorescence intensity and tumor-to-background ratio, which was defined as the fluorescence intensity ratio between tumor and background autofluorescence, were automatically calculated by the software. Mice were also imaged on a Siemens Inveon Micro CT (Siemens, Munich, Germany). Three dimension CT images or movies were reconstructed by Inveon Acquisition Workplace (Siemens, Munich, Germany). For detection of metastatic nodules, Inveon PET (Siemens Medical Solutions, Malvern, Pennsylvania) was used to detect 18 F-FDG signal in tumor in the lungs.
Immunohistochemistry. Tumor tissue specimens were fixed in 4% paraformaldehyde and embedded in paraffin and then sectioned (4 μ m in thickness). Immunohistochemistry was performed using the IHC-P method as instructed by the manufacturer (Abcam, Cambridge, Massachusetts). The tissue sections were incubated with monoclonal mouse anti-human CXCR4 antibodies (R&D Systems), and then with multi-use secondary antibody (Dako, Glostrup, Denmark). The tissue sections were visualized with the EnVisionTM Peroxidase/DAB Rabbit/Mouse detection kit (Gene Tech, Shanghai, China). In negative controls, PBS was used instead of primary antibodies. The immunostaining results were evaluated as previously described 7 .
Statistical analysis. All data were presented as mean ± SD and analyzed using the SPSS 13.0 software (SPSS Inc., Chicago, Illinois). Regions of interest (ROIs) were quantified using the open-source software Image J (http://rsbweb.nih.gov/ij/). Fluorescence intensity of different tissues was defined as the mean fluorescence intensity of the ROI. Tumor-to-background ratios were calculated as previously described 28 . Significance of difference was analyzed with a two-sided Student's t test and p < 0.05 were considered statistically significant.
